Search

Background: The most common hematological abnormality among people infected with Human Immunodeficiency Virus (HIV) is anemia. This is also related to high mortality risk among patients receiving Antiretroviral Therapy (ART). Purpose: This study aimed to identify predictors of anemia among HIV patients taking ART using a regimen of the single-tablet drug contain tenofovir, lamivudine, and efavirenz in Jayapura, Papua. Methods: This was a cross-sectional study conducted at Jayapura regional hospital from June to September 2017. A total of 80 HIV patients were eligible for analysis. Data collection was conducted through an interview, medical record, measurement, and laboratory assay. The significance of differences among categorical variables was analyzed using Fisher's exact test. The variables with p < 0.25 were then analyzed using binary logistic regression to determine predictors associated with anemia. A threshold of p < 0.05 indicates statistical significance. Results: This study showed that Body Mass Index (BMI) <18.50 (p = 0.01; OR = 5.63; 95% CI = 1.43 < OR < 22.19), length on ART =12 months (p = 0.00; OR = 4.90; 95% CI = 1.65 < OR < 14.53), and Cluster of Differentiation 4 (CD4+) percentage out of normal (p = 0.02; OR = 0.19; 95% CI = 0.05 < OR <0.77) had a significant association with anemia. Conclusion: BMI, length on ART, and CD4+ percentage were predictors of anemia among HIV patients taking antiretroviral therapy containing tenofovir, lamivudine, and efavirenz regimen in Jayapura. [ABSTRACT FROM AUTHOR]

Background and aim: HIV/AIDS drugs usually have undesirable side effect. Moringa oleifera is a plant that has been uses for various beneficial purposes. The aim of this study is to investigate the potential benefits of Moringa oleifera on blood triglyceride and low density lipoprotein (LDL) levels in patient receiving tenofovir/lamivudine/efavirenz (TLE) combination therapy. Methods: The protocol was designed as a Longitudinal Randomized Comparative Trial (LRCT) involving 140 HIV adult subjects (56 men and 84 women) who had already been on TLE (300/300/600mg) combination therapy for at least 6 months prior to the study. They were enrolled from a teaching hospital in Nigeria. M. oleifera capsules (200mg) were given to the subjects to be used from the first day as visit 0 until visit 1 (four weeks after) and 2 (12 weeks after). Blood samples of subjects were collected at visits 0, 1 and 2 and serum analyzed for triglyceride and LDL levels Results: There was a significant decrease in serum LDL level (p

Objective: To assess the efficacy and safety of a new single-tablet regimen (STR) of tenofovir disoproxil fumarate (TDF) 300 mg, lamivudine (3TC) 300 mg, and efavirenz (EFV) 600 mg in HIV-infected Thai patients. Methods: This was a prospective study performed for 144 weeks among 51 treatment-naïve patients and 49 experienced patients on separate tablets of TDF, 3TC, and EFV with HIV RNA